Quantitative proteomic analysis of PCSK9 gain of function in human hepatic HuH7 cells
- PMID: 21332221
- DOI: 10.1021/pr2000072
Quantitative proteomic analysis of PCSK9 gain of function in human hepatic HuH7 cells
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in cholesterol homeostasis, mediating degradation of the liver low-density lipoprotein receptor (LDLR). In fact, gain- and loss-of-function PCSK9 variations in human populations associate with hyper- or hypo- cholesterolemia, respectively. Exactly how PCSK9 promotes degradation of the LDLR, the identity of the other biomolecules involved in this process, and the global effect of PCSK9 on other proteins has not been thoroughly studied. Here we employ stable isotope labeling with amino acids in cell culture (SILAC) to present the first quantitative, subcellular proteomic study of proteins affected by the stable overexpression of a gain-of-function PCSK9 membrane-bound chimera (PCSK9-V5-ACE2) in comparison to control, empty vector transfections in a human hepatocyte (HuH7) cell line. The expression level of 327 of 5790 peptides was modified by PCSK9-V5-ACE2 overexpression. Immunoblotting was carried out for the control transferrin receptor, shown to be unaffected in cells overexpressing PCSK9-V5-ACE2, thus validating our SILAC results. We also used immunoblotting to confirm the novel SILAC results of up- and down-regulation of several proteins in cells overexpressing PCSK9-V5-ACE2. Moreover, we documented the novel down-regulation of the EH domain binding protein-1 (EHBP1) in a transgenic PCSK9 mouse model and its up-regulation in a PCSK9 knockout mouse model.
Similar articles
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.Hepatology. 2008 Aug;48(2):646-54. doi: 10.1002/hep.22354. Hepatology. 2008. PMID: 18666258
-
β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.FEBS J. 2015 Jul;282(14):2682-96. doi: 10.1111/febs.13309. Epub 2015 May 18. FEBS J. 2015. PMID: 25913303 Free PMC article.
-
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.Atherosclerosis. 2012 Feb;220(2):381-6. doi: 10.1016/j.atherosclerosis.2011.11.026. Epub 2011 Nov 25. Atherosclerosis. 2012. PMID: 22176652
-
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23973703 Review.
-
PCSK9: an enigmatic protease.Biochim Biophys Acta. 2008 Apr;1781(4):184-91. doi: 10.1016/j.bbalip.2008.01.003. Epub 2008 Feb 2. Biochim Biophys Acta. 2008. PMID: 18280815 Review.
Cited by
-
An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.J Biol Chem. 2016 Nov 18;291(47):24676-24687. doi: 10.1074/jbc.M116.746883. Epub 2016 Oct 7. J Biol Chem. 2016. PMID: 27758865 Free PMC article.
-
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.Scientifica (Cairo). 2012;2012:927352. doi: 10.6064/2012/927352. Epub 2012 Sep 11. Scientifica (Cairo). 2012. PMID: 24278757 Free PMC article. Review.
-
EHBP1, TUBB, and WWOX SNPs, Gene-Gene and Gene-Environment Interactions on Coronary Artery Disease and Ischemic Stroke.Front Genet. 2022 Apr 26;13:843661. doi: 10.3389/fgene.2022.843661. eCollection 2022. Front Genet. 2022. PMID: 35559044 Free PMC article.
-
Association between the EHBP1 SNPs and dyslipidemia in the end-stage renal disease patients with dialysis in Chinese Han population.Lipids Health Dis. 2024 Dec 27;23(1):422. doi: 10.1186/s12944-024-02407-3. Lipids Health Dis. 2024. PMID: 39731114 Free PMC article.
-
Proteomics and Lipidomics to unveil the contribution of PCSK9 beyond cholesterol lowering: a narrative review.Front Cardiovasc Med. 2023 Jun 12;10:1191303. doi: 10.3389/fcvm.2023.1191303. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37378405 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous